Olympus received an FDA warning letter over quality management systems used at six facilities in Japan, Germany and the U.S.

The FDA’s Warning Letter follows its completion of inspections at six of Olympus’ international manufacturing sites in late 2025.

Olympus Partners is pleased to announce that it has entered into an agreement to sell MEI Industrial Solutions ("MEI") to 26North Partners LP. MEI is a scaled national provider of equipment execution ...

Olympus revealed that it was issued a Warning Letter from the U.S. Food and Drug Administration (FDA) concerning observations ...

Olympus Corp. shares tumbled the most since April 2025 after the US Food and Drug Administration issued a warning letter to ...

Olympus shares suffered their biggest one-day drop in nearly 15 years after the U.S. Food and Drug Administration issued a new warning following inspections of some facilities. Shares of the Japanese ...

Olympus results come November 10, 2026. Olympus stock closed at JPY 1,690.00 on October 16, 2026, down 1.80 percent versus ...

Despite denying persistent rumors that it would exit the camera business, Olympus is doing exactly that. The company has announced that will sell its camera business to Japan Industrial Partners (JIP) ...

Investing.com -- Olympus (TYO:7733) shares slumped to a 12-week low on Tuesday after the Japanese medical-device maker disclosed a U.S. Food and Drug Administration warning letter raising concerns ...